BG102476A - Polymorphous forms of secretagogue of growth hormone - Google Patents
Polymorphous forms of secretagogue of growth hormoneInfo
- Publication number
- BG102476A BG102476A BG102476A BG10247698A BG102476A BG 102476 A BG102476 A BG 102476A BG 102476 A BG102476 A BG 102476A BG 10247698 A BG10247698 A BG 10247698A BG 102476 A BG102476 A BG 102476A
- Authority
- BG
- Bulgaria
- Prior art keywords
- forms
- polymorphous forms
- secretagogue
- phenylmethoxy
- propanamide
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 3
- 108010051696 Growth Hormone Proteins 0.000 title abstract 3
- 239000000122 growth hormone Substances 0.000 title abstract 3
- 230000000580 secretagogue effect Effects 0.000 title abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- -1 1,2-dihydro-1-methanesulphonylspiro[3H-indole-3,4'-piperidin]-1'-yl Chemical group 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The invention relates to polymorphous forms of the compoundN-[1(R)-[1,2-dihydro-1-methanesulphanylspiro[3H-indole-3,4'-piperidin]-1'-yl]carbonyl]-2-(phenylmethoxy)ethyl]-2-amino-2-methyl-propanamide methynosulphanate. It is a secretagogue of a growthhormone and is useful for feeding animals for increasing theirgrowth in this way increasing the effectivity of the production ofmeat foodstuffs. In humans it is used for the treatment ofphysiological or medical conditions characterizing by reducedgrowth hormone secretion and of medical states which are improvedfrom anabolic effects of a growth hormone. The momentouspolymorphous forms have advantages before other known forms ofN-[1(R)-[(1,2-dihydro-1-methanesulphonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethoxy)ethyl]-2-amino-2-methyl-propanamide methanesulphonate towards the thermodynamic stability andby the fact that they are suitable to be included inpharmaceutical formulations. The invention also relates toprocesses for the production of these polymorphous forms, topharmaceutical formulations including them as active ingredientsand to the use of the polymorphous forms of the compound and theirformulations for the treatment of some deviations.28 claims
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US590095P | 1995-10-27 | 1995-10-27 | |
| GBGB9603361.8A GB9603361D0 (en) | 1996-02-16 | 1996-02-16 | Polymorphic forms of a growth hormone secretagogue |
| PCT/US1996/016955 WO1997015574A1 (en) | 1995-10-27 | 1996-10-23 | Polymorphic forms of a growth hormone secretagogue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG102476A true BG102476A (en) | 1999-04-30 |
Family
ID=26308741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102476A BG102476A (en) | 1995-10-27 | 1998-05-21 | Polymorphous forms of secretagogue of growth hormone |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1019402A1 (en) |
| JP (1) | JP3204266B2 (en) |
| KR (1) | KR19990067098A (en) |
| CN (1) | CN1067687C (en) |
| AU (1) | AU707946B2 (en) |
| BG (1) | BG102476A (en) |
| BR (1) | BR9611229A (en) |
| CA (1) | CA2235371A1 (en) |
| CO (1) | CO4770956A1 (en) |
| CZ (1) | CZ128098A3 (en) |
| EA (1) | EA000528B1 (en) |
| EE (1) | EE9800147A (en) |
| HU (1) | HUP9902208A3 (en) |
| IS (1) | IS4721A (en) |
| NO (1) | NO310556B1 (en) |
| NZ (1) | NZ321370A (en) |
| PL (1) | PL327511A1 (en) |
| SK (1) | SK51398A3 (en) |
| TR (1) | TR199800726T2 (en) |
| WO (1) | WO1997015574A1 (en) |
| YU (1) | YU56696A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046333A (en) * | 1996-10-25 | 2000-04-04 | Merck & Co., Inc. | Convergent process for the preparation of a growth hormone secretagogue |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ258412A (en) * | 1992-12-11 | 1997-01-29 | Merck & Co Inc | Spiro-fused piperidine derivatives and pharmaceutical compositions |
-
1996
- 1996-10-23 WO PCT/US1996/016955 patent/WO1997015574A1/en not_active Ceased
- 1996-10-23 CN CN96199328A patent/CN1067687C/en not_active Expired - Lifetime
- 1996-10-23 SK SK513-98A patent/SK51398A3/en unknown
- 1996-10-23 KR KR1019980703038A patent/KR19990067098A/en not_active Withdrawn
- 1996-10-23 AU AU74686/96A patent/AU707946B2/en not_active Expired
- 1996-10-23 CA CA002235371A patent/CA2235371A1/en not_active Abandoned
- 1996-10-23 TR TR1998/00726T patent/TR199800726T2/en unknown
- 1996-10-23 EP EP96936869A patent/EP1019402A1/en not_active Withdrawn
- 1996-10-23 EA EA199800335A patent/EA000528B1/en not_active IP Right Cessation
- 1996-10-23 CZ CZ981280A patent/CZ128098A3/en unknown
- 1996-10-23 JP JP51673797A patent/JP3204266B2/en not_active Expired - Lifetime
- 1996-10-23 HU HU9902208A patent/HUP9902208A3/en unknown
- 1996-10-23 EE EE9800147A patent/EE9800147A/en unknown
- 1996-10-23 BR BR9611229A patent/BR9611229A/en not_active IP Right Cessation
- 1996-10-23 NZ NZ321370A patent/NZ321370A/en not_active IP Right Cessation
- 1996-10-23 PL PL96327511A patent/PL327511A1/en unknown
- 1996-10-25 CO CO96056663A patent/CO4770956A1/en unknown
- 1996-10-25 YU YU56696A patent/YU56696A/en unknown
-
1998
- 1998-04-21 IS IS4721A patent/IS4721A/en unknown
- 1998-04-24 NO NO19981867A patent/NO310556B1/en not_active IP Right Cessation
- 1998-05-21 BG BG102476A patent/BG102476A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO310556B1 (en) | 2001-07-23 |
| SK51398A3 (en) | 1998-12-02 |
| KR19990067098A (en) | 1999-08-16 |
| AU707946B2 (en) | 1999-07-22 |
| JP3204266B2 (en) | 2001-09-04 |
| BR9611229A (en) | 1999-05-25 |
| WO1997015574A1 (en) | 1997-05-01 |
| CN1067687C (en) | 2001-06-27 |
| NZ321370A (en) | 1999-11-29 |
| CZ128098A3 (en) | 1998-09-16 |
| YU56696A (en) | 1999-09-27 |
| HK1017894A1 (en) | 1999-12-03 |
| EA199800335A1 (en) | 1998-12-24 |
| EA000528B1 (en) | 1999-10-28 |
| CO4770956A1 (en) | 1999-04-30 |
| HUP9902208A2 (en) | 1999-10-28 |
| HUP9902208A3 (en) | 2001-05-28 |
| IS4721A (en) | 1998-04-21 |
| NO981867D0 (en) | 1998-04-24 |
| JPH10512295A (en) | 1998-11-24 |
| EE9800147A (en) | 1998-12-15 |
| TR199800726T2 (en) | 1998-08-21 |
| CN1205703A (en) | 1999-01-20 |
| PL327511A1 (en) | 1998-12-21 |
| MX9803351A (en) | 1998-09-30 |
| CA2235371A1 (en) | 1997-05-01 |
| AU7468696A (en) | 1997-05-15 |
| NO981867L (en) | 1998-06-29 |
| EP1019402A1 (en) | 2000-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2110670A1 (en) | Spiro piperidines and homologs which promote release of growth hormone | |
| RU95113347A (en) | Spiropiperidines and their homologs, method of synthesis, method of increase of endogenous growth hormone level, method of treatment of osteoporosis, pharmaceutical composition | |
| ZA200104396B (en) | Compositions and methods for stimulating gastrointestinal motility. | |
| ES8402313A1 (en) | Derivatives of amides of carboxylic acids in which the N atom is substituted by a glycosyl radical, method for their preparation and their use to influence the immunogenic system. | |
| PH25504A (en) | Novel substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides pharmaceutical composition containing said compound, method of use thereof | |
| AU5232193A (en) | Spiro piperidines and homologs promote release of growth hormone | |
| HUT45531A (en) | Process for producing bactericidal compositions, fodder additives and 7-azabicycloalkyl-quinolonecarboxylic acid and naphthiridinecarboxylic acid derivatives applicable as active ingredient | |
| MX9706689A (en) | Treatment of cytokine growth factor caused disorders. | |
| HUT55034A (en) | Process for producing peptides with hemoregulating effect and pharmaceutical compositions comprising such compounds as active ingredient | |
| ZA931677B (en) | Process for the preparation of beta-phenylisoserine and analogues thereof | |
| WO2001026650A3 (en) | Use of n-acyl homoserine lactones for the treatment of cardiac tachyarrhythmias, ischaemic heart disease or congestive heart failure | |
| GB9109972D0 (en) | Therapeutic compounds | |
| HUT57204A (en) | Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them | |
| BG102476A (en) | Polymorphous forms of secretagogue of growth hormone | |
| AU558679B2 (en) | Animal feed composition comprising alyl peptides | |
| HUT54358A (en) | Process for producing substituted 1,3,5-triazinetrione derivatives and medical compositions comprising such compounds as active ingredient | |
| HUT48871A (en) | Herbicidal compositions and process for producing substituted tetrahydrophtalimide derivatives applicable as active ingredient | |
| EP1200432A4 (en) | AMIDO-SPIROPIPERIDINES PROMOTING THE RELEASE OF GROWTH HORMONE | |
| BR9911756A (en) | Compound, use of a growth hormone secretagogue or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method to stimulate the release of growth hormone by a mammal's pituitary, and use of a compound | |
| NZ503027A (en) | Use of rifamycin derivative for treating mastitis in a domestic animal | |
| ATE184489T1 (en) | TREATMENT OF LACK OF MILK SECTION IN HUMAN BEINGS | |
| RU93048128A (en) | STIMULATION OF PIG GROWTH | |
| NO921595L (en) | SUPERACTIVE GRF ANALOGS | |
| MX9803316A (en) | Process for the preparation of a growth hormone secretagogue. | |
| GR3024743T3 (en) | Cephem compounds with antimicrobial activity. |